Gender and cutaneous melanoma.
Current evidence suggesting that a patient's sex is relevant to the progression of cutaneous melanoma is largely epidemiological. Although databases of patients with melanomas have for many years shown a survival advantage for female patients with primary melanoma, it has been difficult to evaluate contribution of other known prognostic variables such as thickness and site of the primary tumour, factors which also tend to be related to sex. In addition, there are data from a limited number of experimental studies and clinical trials which support the concept of female survival superiority in melanoma. This paper attempts to summarize the evidence for gender being an important factor in melanoma survival.
Miller
J G
JG
Department of Plastic, Reconstructive and Burns Surgery, Northern General Hospital, Sheffield, UK.
Mac Neil
S
S
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality*; D011987:Receptors, Steroid / Q000502:physiology; D012737:Sex Factors; D012878:Skin Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality*; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D011987:Receptors, Steroid; D013629:Tamoxifen